Company intelligence / Profile preview

Shanxi Taxus Pharmaceuticals

Jinzhong, Shanxi, China

Ownership: Private
Development stage: Other

Overview

Shanxi Taxus was focused on developing paclitaxel for cancer treatment and, through its collaboration with Cardium Therapeutics, on commercializing regenerative therapeutics including Generx (gene therapy for cardiac applications) and Excellagen (acellular biological skin substitute for wound care).

Therapeutic areas: CardiovascularEndocrinologyDermatologyInfectious DiseasesMetabolic DisordersOncology
Modalities: Small moleculeGene therapyBiological products
Industry: Biotech

Partnerships

Cardium Therapeutics (strategic collaboration and funding arrangement)Merck & Co (mentioned as example of Chinese pharma partnerships)Activation Therapeutics (license agreement as of April 2020)

Beyond the preview

Go deeper on Shanxi Taxus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanxi Taxus Pharmaceuticals.

Explore the full profile